BACKGROUND: Addenbrooke's Cognitive Examination III (ACE-III) is a screening test that was recently validated for diagnosing dementia. Since it assesses attention, language, memory, fluency, and visuospatial function separately, it may also be useful for general neuropsychological assessments. The aim of this study was to analyze the tool's ability to detect early stages of Alzheimer's disease and to examine the correlation between ACE-III scores and scores on standardized neuropsychological tests. METHODS: Our study included 200 participants categorized as follows: 25 healthy controls, 48 individuals with subjective memory complaints, 47 patients with amnestic mild cognitive impairment and 47 mild Alzheimer's disease, and 33 patients with other neurodegenerative diseases. RESULTS: The ACE-III memory and language domains were highly correlated with the neuropsychological tests specific to those domains (Pearson correlation coefficient of 0.806 for total delayed recall on the Free and Cued Selective Reminding Test vs. 0.744 on the Boston Naming Test). ACE-III scores discriminated between controls and patients with amnestic mild cognitive impairment (AUC: 0.906), and between controls and patients with mild Alzheimer's disease (AUC: 0.978). CONCLUSION: Our results suggest that ACE-III is a useful neuropsychological test for assessing the cognitive domains of attention, language, memory, and visuospatial function. It also enables detection of Alzheimer's disease in early stages.
BACKGROUND:Addenbrooke's Cognitive Examination III (ACE-III) is a screening test that was recently validated for diagnosing dementia. Since it assesses attention, language, memory, fluency, and visuospatial function separately, it may also be useful for general neuropsychological assessments. The aim of this study was to analyze the tool's ability to detect early stages of Alzheimer's disease and to examine the correlation between ACE-III scores and scores on standardized neuropsychological tests. METHODS: Our study included 200 participants categorized as follows: 25 healthy controls, 48 individuals with subjective memory complaints, 47 patients with amnestic mild cognitive impairment and 47 mild Alzheimer's disease, and 33 patients with other neurodegenerative diseases. RESULTS: The ACE-III memory and language domains were highly correlated with the neuropsychological tests specific to those domains (Pearson correlation coefficient of 0.806 for total delayed recall on the Free and Cued Selective Reminding Test vs. 0.744 on the Boston Naming Test). ACE-III scores discriminated between controls and patients with amnestic mild cognitive impairment (AUC: 0.906), and between controls and patients with mild Alzheimer's disease (AUC: 0.978). CONCLUSION: Our results suggest that ACE-III is a useful neuropsychological test for assessing the cognitive domains of attention, language, memory, and visuospatial function. It also enables detection of Alzheimer's disease in early stages.
Authors: Gillian Coughlan; Antoine Coutrot; Mizanur Khondoker; Anne-Marie Minihane; Hugo Spiers; Michael Hornberger Journal: Proc Natl Acad Sci U S A Date: 2019-04-23 Impact factor: 11.205
Authors: Morris Freedman; Larry Leach; M Carmela Tartaglia; Kathryn A Stokes; Yael Goldberg; Robyn Spring; Nima Nourhaghighi; Tom Gee; Stephen C Strother; Mohammad O Alhaj; Michael Borrie; Sultan Darvesh; Alita Fernandez; Corinne E Fischer; Jennifer Fogarty; Barry D Greenberg; Michelle Gyenes; Nathan Herrmann; Ron Keren; Josh Kirstein; Sanjeev Kumar; Benjamin Lam; Suvendrini Lena; Mary Pat McAndrews; Gary Naglie; Robert Partridge; Tarek K Rajji; William Reichmann; M Uri Wolf; Nicolaas P L G Verhoeff; Jordana L Waserman; Sandra E Black; David F Tang-Wai Journal: Alzheimers Res Ther Date: 2018-07-18 Impact factor: 6.982